Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today reported additional clinical research results from its TELO-MRD program for multiple myeloma, including a comparison of blood-based TELO enumeration with matched bone marrow Adaptive clonoSEQ...